NCT00154349
Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia treatment 2 completed NCT01883219
TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia No drug interventions treatment 2 unknown_status NCT03624530
Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants treatment 2 / 3 unknown_status NCT00860535
Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED) No drug interventions diagnostic 1 terminated NCT03589326
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia treatment 3 active_not_recruiting NCT03595917
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML treatment 1 recruiting NCT01667133
A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) treatment 1 / 2 completed NCT01592136
Expanded Access Program of Ponatinib Not Available Not Available approved_for_marketing NCT01066468
Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders. Not Available 1 terminated NCT01207440
Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) treatment 2 completed NCT02690922
Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients treatment 4 unknown_status NCT04747912
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO) treatment 2 recruiting NCT01491763
Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE treatment 4 unknown_status NCT01376427
Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 Years treatment Not Available unknown_status NCT00109707
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies treatment 1 / 2 completed NCT00384228
A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL treatment 1 / 2 completed NCT04722848
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL treatment 3 recruiting NCT03678454
Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium No drug interventions Not Available Not Available completed NCT06051409
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL. treatment 3 recruiting NCT05603156
A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive treatment Not Available not_yet_recruiting NCT04554459
Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL treatment 2 terminated NCT01028716
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies treatment 2 terminated NCT01030718
Rollover Study of BMS-354825 in Patients With CML and Ph+ALL treatment 1 / 2 completed NCT05594784
Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL treatment 2 recruiting NCT06061094
Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT treatment 2 recruiting NCT03414450
Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies treatment 1 withdrawn NCT01528085
Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia treatment 2 completed NCT02081378
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL treatment 1 completed NCT03647215
CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey No drug interventions Not Available Not Available completed NCT03709017
Iclusig PMS in CML or Ph+ALL Patients Not Available Not Available active_not_recruiting NCT01222013
Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) treatment 2 suspended NCT06481228
Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL treatment Not Available not_yet_recruiting NCT00500006
A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED) treatment 1 terminated NCT00907517
Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247) treatment 1 terminated NCT00199186
Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL) treatment 2 unknown_status NCT04260022
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL treatment 1 recruiting NCT01761682
Acute Lymphoblastic Leukemia Registry at Asan Medical Center No drug interventions Not Available Not Available terminated NCT00101595
Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia treatment 2 completed NCT01914484
Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia treatment 1 / 2 completed NCT01724879
Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL) treatment 2 completed NCT00123487
Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML treatment 3 completed NCT00464113
Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia treatment 1 terminated NCT01100658
Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors treatment Not Available terminated NCT05495035
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL treatment 1 recruiting NCT03821727
SCT in Ph Positive Acute Lymphoblastic Leukemia No drug interventions Not Available Not Available completed NCT00103701
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia treatment 1 completed NCT01310010
Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia treatment 2 completed NCT05024357
A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL treatment Not Available unknown_status NCT05026229
A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL treatment Not Available unknown_status